MOMA

MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Pharmaceutical, Health, Oncology, MOMA, Georgetown University Law Center, Eli Lilly, Growth, Learning, Science, Partnership, Boehringer Ingelheim, Patient, SVP, Roche, Acquisition, Cancer, IPO, Thought, MBA, Doctor of Philosophy, Investigational New Drug, Johns Hopkins University, Therapy, Heart, Eli Lilly and Company, FDA, Knowledge

MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced that Jullian G. Jones, Ph.D., J.D., MBA, has been appointed as the company’s chief business officer.

Key Points: 
  • MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced that Jullian G. Jones, Ph.D., J.D., MBA, has been appointed as the company’s chief business officer.
  • “We are thrilled to welcome Jullian to MOMA.
  • She has an exceptional track record of thinking and acting strategically and creatively across different business dimensions, while leading with heart and a passion for mentorship,” said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA.
  • “Jullian’s expertise is perfectly aligned with MOMA’s business needs at this stage of our growth and positions us more strongly for success.

MOMA Therapeutics Announces Five-Year Discovery Collaboration with Roche Focused on Critical Cancer Dependencies

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Health Technology, General Health, Pharmaceutical, Biotechnology, Sequence homology, Knowledge, Partnership, Drug discovery, Survival, ATPase, IND, Therapy, MOMA, Cancer, ROG, Patient, Fine chemical

MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to announce a strategic collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY).

Key Points: 
  • MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to announce a strategic collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY).
  • This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival.
  • The vision for this collaboration was crafted jointly with Roche to enable each party to bring its strengths in pursuit of this shared goal.
  • “We are excited to join forces with MOMA, combining our leadership in oncology with MOMA’s deep expertise in drug discovery for difficult-to-drug and novel targets in oncology.

American Artist Jean-Michel Basquiat's Masterpiece '200 Yen' to Enchant Top U.S. Museums

Retrieved on: 
Wednesday, December 13, 2023
Opium, MOMA, Marketing, Opium Wars, Museum, Commerce, United States dollar, Movement, Video game

In the latest development, the company announces the upcoming bid by top museums in the United States to feature this major work in their prestigious exhibition displays.

Key Points: 
  • In the latest development, the company announces the upcoming bid by top museums in the United States to feature this major work in their prestigious exhibition displays.
  • Renowned American artist Jean-Michel Basquiat's iconic painting, '200 Yen', previously auctioned by LiveAuctioneers on April 21st, 2020 (lot 018), is poised to make a resounding return.
  • His works soon commanded top prices globally, with pieces showcased in prestigious museums, including the MOMA.
  • The upcoming bid war among top U.S. museums promises an exciting chapter for art enthusiasts and collectors alike.

Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor

Retrieved on: 
Tuesday, October 24, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, MOMA, Food, Rare, Georgetown University, MBA, Growth, Medicine, Safety, Cancer, Therapy, Patient, Food and Drug Administration, Pharmaceutical industry, Scorpion, Indiana University

Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Jeff Albers as a strategic advisor to the company.

Key Points: 
  • Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Jeff Albers as a strategic advisor to the company.
  • Mr. Albers is a seasoned industry leader, with experience building early-stage precision medicine companies into fully integrated commercial organizations delivering targeted medicines to patients.
  • “We are delighted to welcome Jeff as an advisor,” said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion.
  • He currently serves as board chairman at Blueprint Medicines, MOMA Therapeutics and Pheon Therapeutics, board director at Kymera Therapeutics, and board advisor for Life Sciences Cares.

BREATHE! Convention Charts New Territory with World's Largest Communal NFT

Retrieved on: 
Monday, June 19, 2023
Tezos, Creativity, 3D, MOMA, NFT, Convention, FOMO, Guinness, Cryptocurrency, Web3

Convention, a leading event in the emerging tech space, proudly announces a groundbreaking endeavor to set a new Guinness World Record with the creation of the World's Largest Communal NFT, during its upcoming convention in Las Vegas from September 13 to 15, 2023.

Key Points: 
  • Convention, a leading event in the emerging tech space, proudly announces a groundbreaking endeavor to set a new Guinness World Record with the creation of the World's Largest Communal NFT, during its upcoming convention in Las Vegas from September 13 to 15, 2023.
  • "As we merge art, technology, and community to create the world's largest communal NFT, we're tapping into the collective creativity of the Web3 community," said Aaron Vick.
  • Convention is spearheading the creation of the world's largest communal NFT, an embodiment of the future," said Shawn Willis, our CEO and Founder.
  • Convention, the World's Biggest Communal NFT, and how to attend, please visit www.breatheconvention.com.

Film on Women's Rights in El Salvador Brings Issue to World Stage

Retrieved on: 
Monday, April 3, 2023
Rape, Executive producer, Poverty, Reproductive rights, Freedom, American Cinema Editors, Life, HBO, Enzian, Hope, Primetime Emmy Award for Outstanding Picture Editing for a Comedy Series, Woman, Human, Organization, MOMA, Couple in The Cage: Two Undiscovered Amerindians Visit the West, Collection, Museum, Character, Enzian Theater, Salvadorans, Film industry, Birth control, Entertainment, Central Florida

NEW YORK, April 3, 2023 /PRNewswire/ -- Heredia Pictures announced that their gripping documentary short, Imelda Is Not Alone, has been accepted to the Oscar®-qualifying 32nd Florida International Film Festival(FIFF) and will be screening on April  18 and 21 in Winter Park, Florida. 

Key Points: 
  • Imelda Is Not Alone, is the story of a teenager trapped in the complex legal system of El Salvador.
  • The film's Executive Producer and Director is Award-winning Filmmaker Paula Heredia, a prominent voice coming from El Salvador.
  • Our wish is that this film gives insight and hope to women fighting to maintain their basic human and reproductive rights.
  • Imelda Is not alone, reflects a deeply unjust reality faced by young women living in poverty in El Salvador.

Impact Podcast with John Shegerian Features The Carbonauts’ Graham Hill

Retrieved on: 
Wednesday, March 8, 2023
Environmental Issues, Environment, Entertainment, Podcast, Sustainability, General Motors, ERI, FedEx, Gap Inc., Waste management, Seventh generation, Comerica, BMW, Panasonic, Electronics, Virginity, NBA, JetBlue, Ford, Intel, Beyond Meat, UPS, Procter & Gamble, Hertz, The Home Depot, TIME, Adobe, EPAM, GE, IBM, Molson Coors, Google Podcasts, Discovery, Goodyear Tire and Rubber Company, Dell, Johnson & Johnson, Tree hugger, T. Rowe Price, Best Buy, Behavior, Eurosport 1, Texas Instruments, Architecture, Hill, The Hershey Company, MOMA, Entrepreneurship, Ball Corporation, Amazon Music, Verizon Communications, Homeboy Industries, Thrive Market, Kimberly-Clark, FICO, Music, Samsung, Spotify, NVIDIA, Amazon, Qualcomm, Unilever

Graham Hill, Founder and CEO of The Carbonauts , is the featured guest this week on the Impact Podcast with John Shegerian .

Key Points: 
  • Graham Hill, Founder and CEO of The Carbonauts , is the featured guest this week on the Impact Podcast with John Shegerian .
  • The Carbonauts helps Fortune 1000 companies build climate-literate, sustainability enthusiastic cultures via tools such as live, interactive sustainability workshops.
  • “It was an honor to have Graham, a true sustainability innovation leader, on our show,” said Shegerian.
  • The Impact Podcast with John Shegerian is available for listening on ImpactPodcast.com , Apple’s iTunes , Amazon Music, Google Podcasts , Spotify , libsyn , and as part of iHeartRadio’s digital broadcast, reaching over 120 million users.

MOMA Therapeutics Appoints Industry Leader Jeff Albers as Chair of the Board of Directors

Retrieved on: 
Wednesday, February 8, 2023
Biotechnology, Pharmaceutical, Health, Oncology, MBA, Medicine, Therapy, Genzyme, Atlas Venture, Acquisition, Bayer, Georgetown University, Food, Investigational New Drug, MOMA, ATPase, FDA, Knowledge, Hematology, Regulation of tobacco by the U.S. Food and Drug Administration, Atlas, Cancer, IND, Pharmaceutical industry, Management, Indiana University, Algeta

MOMA Therapeutics, a biopharmaceutical company discovering a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced the appointment of Jeff Albers as independent chairperson of the company’s board of directors.

Key Points: 
  • MOMA Therapeutics, a biopharmaceutical company discovering a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced the appointment of Jeff Albers as independent chairperson of the company’s board of directors.
  • “Jeff is a seasoned industry leader who is widely recognized for his strategic thinking, humility and breadth of experience,” said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA.
  • “I am excited to partner with MOMA during this critical phase of the company’s evolution,” said Mr. Albers.
  • Mr. Albers is currently board chairman of Blueprint Medicines and sits on the board of directors of Kymera Therapeutics and Magenta Therapeutics; he is also a venture partner at Atlas Ventures and serves on the board of advisors for Life Sciences Cares.

Hollyland Starts Building Wireless Solution Ecosystem for Global Video Production Industry

Retrieved on: 
Friday, December 30, 2022
Online, Ecosystem, COVID-19, ABS, Aputure, Communication, Antenna (radio), Social media, Hygiene, Health, MOMA, Marketing, HD, DECT, Chinese, Guideline, Multimedia, IBC, Livestreaming, Dream, PC, Electronics, Feedback, Inter, NAB, Nikon, Sale, Bullet, Video game console, Retail, Mobile phone

Even so, we're much proud that we managed to deliver new lineups as planned and started building wireless solution ecosystem for video creators.

Key Points: 
  • Even so, we're much proud that we managed to deliver new lineups as planned and started building wireless solution ecosystem for video creators.
  • 1 Pioneering Plan -- With the diversified development of Hollyland product lines, we have successfully built Hollyland Wireless Solution Pack.
  • Shenzhen Hollyland Technology Co., Ltd. ('Hollyland' or 'Hollyland Technology') empowers global customers with professional solutions that are expressly designed for wireless data, audio, and video transmission and wireless intercom solutions since 2013.
  • Hollyland serves many markets, including filmmaking, television shooting, video production, broadcast, live streaming, live events, exhibitions, broadcast media, production, general events, theatres, houses of worship, rental houses, and more.

Bruker Launches New nanoElute® 2 nano-LC For 4D-Proteomics, Advances Fluxomics Applications with MetaboScape® 2023 Software

Retrieved on: 
Monday, August 29, 2022
Software, Research, General Health, Pharmaceutical, Hardware, Medical Devices, Technology, Health Technology, Science, Biotechnology, Neurology, Health, Machine learning, Molecular biology, Metabolomics, University, Paser, Lipid, Research, Proteomics, University of Southern Denmark, Life, Protein, Associate, Disease, Solution, MOMA, Pathology, Department, JHSPH Department of Biochemistry and Molecular Biology, Bruker, Mass spectrometry, PPI, Workflow, Biochemistry, Cell, Multimedia, Capillary, Microscopy, Plasma, Karolinska Institute, Nasdaq, IMSC, MALDI, University of Ottawa, CCS, Conference, Cell biology, Risk, Â, International Mass Spectrometry Foundation, Acquisition, ISCB Senior Scientist Award, Mobile phone, Fine chemical, Medical imaging, Cancer

The nanoElute 2 features a further improved nano-LC pump design, and an intuitive and flexible user interface covering a broad range of applications from single-cell proteomics to plasma proteomics.

Key Points: 
  • The nanoElute 2 features a further improved nano-LC pump design, and an intuitive and flexible user interface covering a broad range of applications from single-cell proteomics to plasma proteomics.
  • The nanoElute 2 now also supports the label-free ProteoCHIP for the CellenONE platform for high-sensitivity single cell proteomics.
  • The nanoElute 2 dissolves the tryptic peptides directly in the plate prior to injection, avoiding manual intervention and thus streamlining our workflows.
  • Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.